Swedbank AB Grows Stock Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Swedbank AB increased its stake in Jazz Pharmaceuticals by 10.0% in Q1, owning 1,102,143 shares worth approximately $136.83 million.
• Wall Street analysts have given Jazz Pharmaceuticals a consensus rating of "Moderate Buy." Several firms, including Morgan Stanley and Truist Financial, have recently raised their price targets for the stock.
• Jazz Pharmaceuticals reported a quarterly net loss of ($8.25) EPS, missing estimates, but had revenue of $1.05 billion, reflecting a 2.1% increase compared to the previous year.

Swedbank AB grew its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 10.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,102,143 shares of the specialty pharmaceutical company's stock after acquiring an additional 100,211 shares during the period. Swedbank AB owned 1.82% of Jazz Pharmaceuticals worth $136,831,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Voya Investment Management LLC lifted its position in shares of Jazz Pharmaceuticals by 67.1% in the 1st quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company's stock worth $6,996,000 after purchasing an additional 22,628 shares during the period. Inspire Investing LLC bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $689,000. Strs Ohio bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $2,042,000. Acadian Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $90,000. Finally, Geneos Wealth Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock worth $47,000 after acquiring an additional 137 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Up 3.4%

Shares of NASDAQ JAZZ traded up $4.28 during midday trading on Wednesday, hitting $130.82. The company's stock had a trading volume of 284,164 shares, compared to its average volume of 930,027. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The business's fifty day simple moving average is $119.30 and its two-hundred day simple moving average is $116.30. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The firm has a market capitalization of $7.94 billion, a price-to-earnings ratio of -19.45, a price-to-earnings-growth ratio of 7.76 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. During the same quarter in the prior year, the firm earned $5.30 EPS. The firm's revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Needham & Company LLC restated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target on the stock. Royal Bank Of Canada increased their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a research note on Thursday, August 28th. Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a "buy" rating in a research note on Thursday, August 28th. Finally, Zacks Research upgraded shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Fourteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $178.67.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director directly owned 429,973 shares of the company's stock, valued at $55,303,127.26. The trade was a 1.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.